Skip to main content
Top
Published in: Rheumatology International 6/2010

01-04-2010 | Case Report

Paraneoplastic Raynaud’s phenomenon in a breast cancer survivor

Authors: David Allen, David Robinson, Shikha Mittoo

Published in: Rheumatology International | Issue 6/2010

Login to get access

Abstract

A 35-year-old woman with a history of breast cancer, treated 3 years ago with surgery, radiation, and chemotherapy presented with a rapid onset of severe Raynaud’s phenomenon. On physical examination, she had digital ulcers and splinter hemorrhages; there were no signs of an underlying rheumatic condition. Laboratory evaluation revealed anemia, the presence of antinuclear antibody and slight depression in her serum complement C3 level. The remainder of her serologic evaluation, including extractable nuclear antigens, anti-double-stranded DNA antibody, antiphospholipid antibodies, rheumatoid factor, anti-neutrophil cytoplasmic antibodies, cryoglobulins, and cold agglutins, were negative. Within weeks of her presentation, she developed acute renal failure and bilateral lower extremity edema. A computed tomography scan of her abdomen and pelvis showed bulky lymphadenopathy and hydronephrosis; a pelvic lymph node biopsy revealed metastatic breast cancer. She was initially managed with passive rewarming strategies, topical antibiotics, vasodilator and anti-platelet therapy, but had a negligible response. However, once she was started on chemotherapy for her recurrent malignancy, there was a significant improvement in her Raynaud’s symptoms and resolution of her digital ulcers.
Literature
1.
go back to reference Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud’s phenomenon in general practice. BMJ 301:590–592CrossRefPubMed Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud’s phenomenon in general practice. BMJ 301:590–592CrossRefPubMed
10.
go back to reference Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ (1995) Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A(13–14):2229–2238. doi:10.1016/0959-8049(95)00460-2 CrossRefPubMed Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ (1995) Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A(13–14):2229–2238. doi:10.​1016/​0959-8049(95)00460-2 CrossRefPubMed
11.
go back to reference Reiser M, Bruns C, Hartmann P, Salzberger B, Diehl V, Fatkenheuer G (1998) Raynaud’s phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi’s sarcoma. Eur J Clin Microbiol Infect Dis 17(1):58–60. doi:10.1007/BF01584368 CrossRefPubMed Reiser M, Bruns C, Hartmann P, Salzberger B, Diehl V, Fatkenheuer G (1998) Raynaud’s phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi’s sarcoma. Eur J Clin Microbiol Infect Dis 17(1):58–60. doi:10.​1007/​BF01584368 CrossRefPubMed
12.
15.
go back to reference Toumbis-Ioannou E, Cohen PR (1994) Chemotherapy-induced raynaud’s phenomenon. Cleve Clin J Med 3:195–199 Toumbis-Ioannou E, Cohen PR (1994) Chemotherapy-induced raynaud’s phenomenon. Cleve Clin J Med 3:195–199
18.
go back to reference Saiki M, Sakai K, Saiki S, Kitagawa Y, Nakanishi M, Hirose G (2005) Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization. J Autoimmun 24:203–208. doi:10.1016/j.jaut.2005.01.008 CrossRefPubMed Saiki M, Sakai K, Saiki S, Kitagawa Y, Nakanishi M, Hirose G (2005) Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization. J Autoimmun 24:203–208. doi:10.​1016/​j.​jaut.​2005.​01.​008 CrossRefPubMed
20.
go back to reference Hansen SW, Olsen N (1989) Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol 7(7):940–942PubMed Hansen SW, Olsen N (1989) Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol 7(7):940–942PubMed
Metadata
Title
Paraneoplastic Raynaud’s phenomenon in a breast cancer survivor
Authors
David Allen
David Robinson
Shikha Mittoo
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0985-5

Other articles of this Issue 6/2010

Rheumatology International 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine